Study Summary
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
Want to learn more about this trial?
Request More InfoInterventions
CEA CAR-T cellsBIOLOGICAL
Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| First affiliated hospital, Zhejiang University | Hangzhou | Zhejiang | China |